Reyvow is a complementary therapy to Eli Lilly’s other migraine drug, Emgality, making Eli Lilly the franchise leader in migraine treatments, according to Endpoints News.
The drug was approved Oct. 11 after two randomized, double-blind placebo-controlled trials with 3,177 adult patients with histories of migraines. The drug was shown to relieve migraine symptoms within two hours.
The most common side effects from Reyvow were dizziness, fatigue, a burning or prickling sensation in the skin, known as paresthesia, and sedation.
The approval of two migraine medications in the last year is rare for Eli Lilly’s historically slow-moving research and development group, according to Endpoints News.
Read the full article here.
More articles on pharmacy:
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
